Project

Randomized phase II study to investigate the efficacy, safety and tolerability of ZK 230211 (25 mg vs. 100 mg) as second-line endocrine therapy for postmenopausal women with hormonereceptor-positive metastatic breast cancer

Completed · 2008 until 2009

Ruhstaller Thomas, Räss Andrea